

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康宁

溫州康寧醫院股份有限公司

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(3300000000000000)

ANNUAL REPORT OF THE COMPANY
FOR THE YEAR ENDED DECEMBER 31, 2015

1. GENERAL INFORMATION

1.1 The board of directors (the **B**) of Wenzhou Kangning Hospital Co., Ltd. (the **C**) is pleased to announce the consolidated annual report of the Company and its subsidiaries (collectively, the **Group**) for the financial year ended December 31, 2015 (the **Report**) with comparative figures of the preceding financial year ended December 31, 2014.

1.2 The financial statements of the Group for the Reporting Period (the **Financial Statements**) are prepared in accordance with the International Financial Reporting Standards (the **IFRS**).

2 FINANCIAL SUMMARY

2.1 2015, 2014, 2013 and 2012

	F 2015 RMB'000	2014 RMB'000	D 2013 RMB'000	31, 2012 RMB'000
Revenue	343,674	296,296	226,363	170,813
Profit before income tax	70,170	68,567	47,576	17,964
Income tax expense	(18,548)	(17,369)	(11,383)	(4,733)
Total comprehensive income	51,622	51,198	36,193	13,231
Attributable to:				
Equity holders of the Company	55,709	51,198	36,193	13,231
Non-controlling interests	(4,087)			
		A 2015 RMB'000	D 2014 RMB'000	31, 2013 RMB'000
Total assets	1,224,434	372,339	305,679	226,667
Total liabilities	262,205	111,249	96,818	202,601
Total equity	962,229	261,090	208,861	24,066
Equity attributable to:				
Equity holders of the Company	959,716	261,090	208,861	24,066
Non-controlling interests	2,513			

3 BACKGROUND AND INTRODUCTION

3.1 Background

In 2015, the Government has implemented the strategic capabilities of the health system, facilitated the development of the health system and improved the operational efficiency of the health system. In 2015, the five health systems established by the Government have been established in the health system, which increased from 1,760 beds in 2014 to 2,010 in 2015, and high utilization rate of beds, which greatly increased the health system.

While consolidating the health system, the government has also made strategic layout like integrating the health system and the health system. In 2015, the Government has implemented the development of the health system of Ya Jia Feng Hospital of Traditional Chinese and Western Medicine* (燕郊輔仁中西醫結合醫院, 燕郊輔仁中西醫結合醫院), the health system of Chengdu Ren Yi Hospital Co., Ltd.* (成都仁一醫院有限公司, a subsidiary of the health system established in the People's Republic of China (the health system Co., Ltd.)). In 2010 and the health system of Chengdu Jihong Hospital Co., Ltd.* (成都濟宏醫院有限公司) in the health system (Jihong Hospital Co., Ltd. 28, 2015) and Beijing Yining Hospital Co., Ltd. (北京怡寧醫院有限公司, Beijing Yining Hospital Co., Ltd.), increasing the beds of the health system facilities from 150 in 2014 to 370 in 2015 and the health system facilities from the health system.

The Government has also believed that the health system is the Government's core competitive advantage and the Government has increased the health system's efficiency and the health system's efficiency. In 2015, the Government's specialized health system, which has been increased to 12, increased to 25 and increased to 5 of which has been increased to the Science Citation Database, and the health system project funded by the National Natural Science Foundation of the health system. And the health system's efficiency and the health system's efficiency, the health system's efficiency and the health system's efficiency. In 2015, the health system's efficiency and the health system's efficiency, the health system's efficiency and the health system's efficiency.

3.2 Background

On January 22, 2016, the Government has implemented (i) a health system of Wenzhou Medical University* (溫州醫科大學) in the health system of the Health System of Wenzhou Medical University* (溫州醫科大學精神醫學學院); and (ii) a health system of Wenzhou Medical University Assets Management Co., Ltd.* (溫州醫科大學資產經營有限公司) and Wenzhou Guoda Information Technology Co., Ltd.* (溫州國大信息科技有限公司) in the health system of 51% of the health system of Wenzhou Guoda Investment Co., Ltd.* (溫州國大投資有限公司).

* For identification purposes only

司) by the Company of Weizhou Medical Unit Asset Management Company Limited through public bidding, subject to the eligibility of the selected shareholder(s). For detail, please refer to the Company's annual general meeting dated January 22, 2016. The Puchiat School of Weizhou Medical Unit was established on March 20, 2016. As of the date of this annual general meeting, the Company has not acquired any interest in Weizhou Guda Investment Company.

On January 28, 2016, the Company entered into a framework agreement with Mr. HUANG Feng and Mr. HUANG Cheng (collectively, the "Huang Family") in relation to (i) the established entity for target company (the "Target Company") by the Vendor; (ii) the established entity for the acquisition of the Target Company by the Vendor; and (iii) the acquisition of 26% equity interest and become a controlling shareholder of the Target Company by the Company (the "Acquisition"). Under the completion of the Proposed Transaction, it is expected that the Company will hold 51% equity interest in the Target Company. For detail, please refer to the Company's annual general meeting dated January 28, 2016. The Target Company was established on February 5, 2016. As of the date of this annual general meeting, the Company has not entered into any agreement in relation to the Proposed Transaction.

On February 22, 2016, the Company entered into a strategic agreement with Shanghai Jiafeng Investment Management Co., Ltd. (上海金浦健服股權投資管理有限公司), Shanghai Yicheng Asset Management Co., Ltd. (上海銀驕資產管理中心(有限合夥)), Chongqing Guiding Industry Fund Co., Ltd. (重慶產業引導股權投資基金有限責任公司), Shandong Xinhua Medical Instrument Co., Ltd. (山東新華醫療器械股份有限公司), Jiangsu Shagang Group Co., Ltd. (江蘇沙鋼集團有限公司) and USUM Investment Group Co., Ltd. (渝商投資集團股份有限公司) in relation to (i) the established entity for Chongqing Jiafeng Healthcare Service Industrial Fund Investment Partnership* (重慶金浦醫療健康服務產業股權投資基金合夥企業 (有限合夥)), (the "Fund"); and (ii) the Company's contribution of RMB50.0 million for the subscription of the Fund. On the same date, the Company and Shanghai Jiafeng, the managing agent of the Fund, entered into a strategic cooperation agreement in relation to, among others, certain rights of the Company as a limited partner of the Fund. For detail, please refer to the Company's annual general meeting dated February 23, 2016. The Fund was established in the PRC on March 22, 2016. As of the date of this annual general meeting, each contributor has been made and the Company expects to make such contribution in 2016.

* For identification purposes only

3.3 B

Looking at the future, the Company will fully leverage the favorable government policies in China which encourage the public to establish medical facilities and attract private and public health care facilities through the existing medical facilities in 2016. It is expected that Li Hai Kaigong Hospital Co., Ltd.* (臨海康寧醫院有限公司) (臨海康寧醫院有限公司) and Weizhou Yiyigong Geiyao Hospital Co., Ltd.* (溫州怡寧老年醫院有限公司) (溫州怡寧老年醫院有限公司), a wholly-owned subsidiary of the Company which was established at the Liaoning Medical Academy in the context of the Company dated November 10, 2015 (the "November 10, 2015 Agreement") and whose principal business is to provide medical services for the geriatric, clinical geriatric, psychiatric, and logical treatment will continue to operate in the first half of 2016. At the same time, the Company will also expand the operation of the existing Pingyang Kaigong Hospital* (平陽康寧醫院), Quzhou Yiyigong Hospital* (衢州怡寧醫院) and Shenzhen Yiyigong Hospital* (深圳怡寧醫院), aiming for the total to operate in the second half of 2016.

Meanwhile, the company has launched the Entrepreneurship Plan for 100 People (百人創業計劃), and will continue to attract and integrate resources and expand the health care facilities of the Group through various channels in 2016. In addition, the Company will continue to adhere to the belief that talent is the core competitive advantage, cooperate with Weizhou Medical University in carrying out the Psychiatric School of Weizhou Medical University to enhance its capabilities in scientific research and talent training, thus forming a full talent pool for the long-term development of the Group.

4 A A E E D C A D A A

4.1 F

4.1.1 Revenue

The Group generates revenue mainly through the following ways: (i) revenue from operating medical facilities, and (ii) management fees for managing health care facilities.

* For identification purposes only

Revenue from operating the Group's owned hospitals

Revenue from operating the Group's owned hospitals consists of fees charged for the inpatient and outpatient services at its various hospitals, including treatment and general healthcare services, pharmaceuticals and ancillary hospital services. The table below sets forth a breakdown of revenue from operating the Group's owned hospitals for the periods indicated:

	F D 2015 (RMB'000)	31, 2014 (RMB'000)
Treatment and general healthcare services	240,103	206,790
Pharmaceuticals	87,740	77,384
Ancillary hospital services	2,270	1,828
Total revenue	330,113	286,002
Costs incurred	206,283	178,766
Gross profit	123,830	107,236

Revenue from the Group's owned hospitals amounted to RMB330.1 million, representing a year-on-year increase of 15.4%, accounting for 96.1% of the total revenue of the Group for the Reporting Period, due to the increase in the overall effective service capacity of the owned hospitals and a decrease in patient and outpatient fees. Patient inpatient fees of the Group's owned hospitals hit a record, with inpatient fees amounting to 129,355 (2014: amounting to 119,425) and inpatient bed-days of 689,244 (2014: 615,242). Average outpatient fees increased to RMB486 (2014: amounting to RMB482), and total average inpatient and outpatient bed charges increased to RMB384 (2014: RMB369), and the highest increase in medical services charged by Cangnan Kangning Hospital Co., Ltd. (蒼南康寧醫院有限公司) and Yongjia Kangning Hospital Co., Ltd. (永嘉康寧醫院有限公司) since March 1, 2015 and January 1, 2015, respectively.

Revenue from treatment and general healthcare services accounted for 72.7% of revenue from operating the owned hospitals (2014: 72.3%), and revenue from pharmaceuticals accounted for 26.6% of revenue from operating the owned hospitals (2014: 27.1%).

Costs incurred by the owned hospitals of the Group include costs of pharmaceuticals and consumables used, electricity fees, depreciation and amortization, and other operating fees.

4.1.2 Gross Profit and Gross Profit Margin

Total gross profit of the Group amounted to RMB130.4 million, representing a year-on-year increase of 13.4%. Overall gross profit margin decreased to 37.9% (2014: 38.8%), reflecting the fact that despite the stabilizing gross profit margin of the Hospital, the three new healthcare facilities under construction incurred a loss in the Reporting Period due to the late start, which had a negative impact on the gross profit margin of the group and the overall increase.

4.1.3 Other Income

Other income of the Group continued to grow steadily and is fully attributable. In 2015, the income amounted to RMB3.1 million, representing a year-on-year increase of 346.2%, mainly due to the growth of the group's subsidiaries.

4.1.4 Selling Expenses

In 2015, the selling expenses of the Group amounted to RMB2.0 million, representing a year-on-year decrease of 5.8%, accounting for 0.6% of the total expenses (2014: 0.7%).

4.1.5 Administrative Expenses

Administrative expenses of the Group mainly consist of employee wages and benefits, depreciation and amortization, administrative staff, rent of the new building of the Hospital and their respective fees, depreciation, amortization and other.

In 2015, administrative expenses of the Group amounted to RMB62.5 million (2014: RMB45.6 million), representing a year-on-year increase of 37.1%, mainly due to: (i) an increase of RMB6.2 million in employee wages and benefits due to (1) the increase in the average salary of each administrative staff and (2) the average-based bonus distributed to the employees of the contributing subsidiaries; (ii) an increase of RMB3.2 million in the rental fee of Weizhuo Yiyi Genetic Hospital, which is set to commence operation; and (iii) an increase of RMB5.2 million in the off-invoice expenses related to the initial public offering.

4.1.6 Finance Income

In 2015, finance income increased to RMB7.6 billion, representing a year-on-year increase of 917.8%, mainly because the proceeds from the initial public offering were deposited in Hong Kong dollars (USD). Higher exchange rate of HK\$ against Renminbi (RMB) increased the realized exchange gain to RMB9.8 billion, which offset the finance expense relating to the payable of RMB4.0 billion.

4.1.7 Share of Loss of Investments Accounted for Using the Equity Method

In 2015, share of loss of investments accounted for using the equity method amounted to RMB6.3 billion (2014: nil), which represented 49% equity interest in Beijing Yiding Hospital, which commenced its operation in September 2015 and recorded a loss after tax of RMB12.8 billion.

4.1.8 Income Tax Expense

In 2015, income tax expense increased to RMB18.5 billion, representing a year-on-year increase of 6.8%, mainly due to the higher effective tax rate of RMB70.2 billion (2014: RMB68.6 billion). On effective tax rate in 2015 and 2014 were 26.4% and 25.3%, respectively.

4.1.9 Net Profit

In 2015, attributable to the shareholders of the Company (the Shareholders) amounted to RMB55.7 billion, representing a year-on-year increase of 8.8% as compared with 2014.

4.2 Financial Results

4.2.1 Inventory

As of December 31, 2015, inventory balance decreased to RMB7.5 billion (as of December 31, 2014: RMB7.9 billion), mainly due to the decrease in pharmaceutical inventory.

4.2.2 Trade Receivables

As of December 31, 2015, the balance of trade receivable increased to RMB123.1 million (as of December 31, 2014: RMB84.5 million), mainly due to: (i) the increase in the average number of days with the billing with the health care facilities; and (ii) the increase in the average trade receivable attributable to medical insurance payment. As of December 31, 2015, 79.5% of trade receivable of the Group were either billed or collected aged within 90 days.

4.2.3 Other Receivables, Deposits and Prepayments

A f Dece be 31, 2015, the ecei able , de il a d e a e t
i c ea ed t RMB91.0 illi (a f Dece be 31, 2014: RMB41.2
illi), i a il d e t : (i) the i c ea e f RMB25.8 illi i
e a e t f e tale e e e elati g t We zh . Yi i g
Ge iat ic H ital; (ii) the i c ea e f RMB13.0 illi elati g t
the e a e t f the cha e fa e t f Pi g a g Ka g i g
H ital C ., Ltd.* (平陽康寧醫院有限公司) (  
  , a  h ll -  ed b idia f the C a); a d (iii) a
l a f RMB12.0 illi  l e te ded t Che gd Re i H ital
C a Li ited b the C a .

4.2.4 Trade Payables

As of December 31, 2015, the identifiable intangible assets were RMB20.0 billion (as of December 31, 2014: RMB23.8 billion), of which the intangible assets with finite lives were RMB19.0 billion.

4.2.5 Accruals and Other Payables

As of December 31, 2015, accumulated the available increased to RMB166.4 billion (as of December 31, 2014: RMB60.0 billion), increased to RMB90.5 billion following the available for contract. Although it is related to the increase of the price, which is related to the actual increase of the price of the Ya Jia Fei Hotel and the increase of the price of the Ya Jia Fei Hotel, aggregated the increase of the price of the Ya Jia Fei Hotel. Please refer to the appendix 4.3.4 below for the details.

4.2.6 Net Current Assets

As of December 31, 2015, the net assets of the Group amounted to RMB664.0 billion (as of December 31, 2014: RMB86.2 billion), of which the net assets of the financial assets amounted to RMB590.7 billion, which are the cash flows of the initial public offering, off-balance sheet liabilities in the amount of RMB50.0 billion, and the net assets of the financial assets of CITIC Bank, which is the net assets of the financial assets.

* For identification purposes only

4.3 现金流量表

The table below sets forth the information extracted from the consolidated cash flow statement of the Group for the period indicated:

	2015 RMB'000	2014 RMB'000
Net cash (used in)/from operating activities	(5,063)	33,328
Net cash used in investing activities	(382,367)	(60,663)
Net cash from/(used in) financing activities	708,785	(2,977)
Net increase/(decrease) in cash and cash equivalents	321,355	(30,312)

4.3.1 Net Cash from Operating Activities

In 2015, net cash inflow from operating activities amounted to RMB5.1 billion. We had net cash generated from operating activities before change in working capital of RMB87.0 billion, mainly due to change in prepayment of RMB70.2 billion and adjustment of depreciation of RMB17.3 billion. Change in working capital resulted in cash inflow of RMB66.4 billion, mainly due to change in prepayment of RMB58.2 billion in trade and receivable advance. The decrease mainly due to: (i) increase in trade and receivable advance due to the completion of health care facilities; and (ii) decrease in trade payable related to Weizhuo Yigong Ge Pharmaceutical. We had net cash inflow of RMB25.7 billion in trade and receivable advance.

4.3.2 Net Cash Used in Investing Activities

In 2015, net cash used in investing activities amounted to RMB382.4 billion, mainly due to: (i) change in prepayment of RMB113.6 billion, change in (1) amount paid and received in trade and exchange of Weizhuo Kangyigong Pharmaceutical and (2) amount paid to acquire Beijing Yigong Pharmaceutical, Lihai Kangyigong Pharmaceutical and Weizhuo Yigong Ge Pharmaceutical in the first half; and (ii) a decrease in initial investment in the three of RMB251.3 billion.

4.3.3 Net Cash from Financing Activities

In 2015, net cash from financing activities amounted to RMB708.8 million, mainly due to: (i) net proceeds from the initial public offering of RMB590.7 million; (ii) net proceeds of RMB78.4 million from the issuance of capital debt; capital contribution by the initial public offering; and (iii) a loan of RMB50.0 million from China CITIC Bank.

4.3.4 Significant Investment, Acquisition and Disposal

The Group entered into a technology license agreement with Ya Jia F. & H. in March 2015 and a license agreement in April 2015. The term of the technology license agreement is from April 2015 to December 2034, extendable if both parties agree thereto within the term. During the term of the agreement, the Group undertakes to provide a license to Ya Jia F. & H. and meet a predetermined schedule for all improvements of the technology. The initial fee for the license begins with RMB2.7 million for the period from April 1, 2015 to December 31, 2015, increases to RMB4.0 million for the year 2016, and thereafter increases by a predetermined fixed rate of 4% to 10% until the year of 2034, for which the initial fee for the license is RMB14.1 million. If Ya Jia F. & H. fails to meet the target, the Group is entitled to contribute the shortfall. On the other hand, the Group is entitled to receive a royalty for the fit (based on total accounts of Ya Jia F. & H.) with certain adjustments agreed by the parties for the technology license agreement with Ya Jia F. & H. In addition, the Group is effectively obligated to assist Ya Jia F. & H. and undertake a portion of the technology license fee to the hospital as the agreed fee. The Group recognizes each contractual right to a share of Ya Jia F. & H. and receives a license fee as a intangible asset of RMB93.1 million on the balance sheet, evaluated initially at the amount calculated by discounting the future cash flows of the license fee using the prevailing market rate.

Since a disclosed above, the Group had significant net cash, activities during 2015.

On February 22, 2016, the Company entered into a agreement to contribute RMB50.0 million to the Internet Fund, which shall improve healthcare and the service industry. In principle, the Internet Fund's investment in the healthcare service industry shall be no less than 80% of its total assets available for investment. For detail, please refer to the announcement of the Company dated February 23, 2016. As of the date of this announcement, each contribution has been made and the Company expects to make each contribution in 2016.

4.3.5 Capital Expenditure

Capital expenditure of the Group is mainly consisted of the following: (i) rent, land and building, construction, leasehold improvement, medical equipment, furniture and office equipment and transport vehicle; (ii) land lease right; and (iii) intangible assets. Capital expenditure of the Group in 2015 was RMB193.4 million, increasing by 163.1% from 2014, mainly due to the acquisition of the lease right of Ya Jia Fei Hospital for 19 years and 9 months at a consideration of RMB93.1 million.

4.3.6 Use of Proceeds from Initial Public Offering

The Board of Directors utilized the net proceeds from the initial public offering with effect to the end of the period disclosed in the Prospectus and confirmed that the actual material change in the intended use of the net proceeds disclosed in the Prospectus. As of December 31, 2015, the Group applied the net proceeds for the following:

RMB20.0 million for the decoration of Weizhen Yiyig
Genetic Hospital; and

RMB20.0 million for contribution to the registered capital fund of
Jiufalata Pigag Kagig Hospital, for which
RMB13.0 million was used for the change of equity.

4.4

4.4.1 Bank Borrowings

As of December 31, 2015, the balance of bank borrowings of the Group amounted to RMB50.0 million (as of December 31, 2014: nil), all denominated in the Renminbi.

4.4.2 Contingent Liabilities

As of December 31, 2015, the Group had no contingent liabilities. The Group guarantees that it would have no material impact on the financial statements of the Group.

4.4.3 Asset Pledge

As of December 31, 2015, none of the Group's assets had been pledged.

4.4.4 Contractual Obligations

The contractual obligations of the Group include commitments for lease agreements. As of December 31, 2015, the future aggregate lease liabilities include non-cancellable lease agreements of RMB209.0 million.

4.4.5 Financial Instruments

Financial instruments of the Group consist of trade receivables, accounts payable, related parties, trade receivables, trade payables, cash and cash equivalents, bank borrowings, trade and other payables. The management manages and monitors the credit risk of the accounts receivable and trade receivables and the credit risk of the trade payables and other payables.

4.4.6 Exposure to Fluctuation in Exchange Rates

The Group does not carry out any financial activities in Hong Kong dollars against RMB. The Group therefore does not face any exchange risk.

The Group has entered a derivative financial instrument to hedge against the exchange rate risk. The management manages the exchange rate risk by entering into the derivative financial instruments to hedge the exchange rate risk. The Group will continue to hedge its exchange rate risk.

4.4.7 Gearing Ratio

As at December 31, 2015, the Group's gearing ratio (total interest-bearing liabilities divided by total assets) was 11.8% (2014: nil).

5 FINANCIAL STATEMENTS

5.1 Statement of Financial Position

The Company's financial statements are prepared in accordance with the Hong Kong Financial Reporting Standards (the "HKFRS") issued by the Hong Kong Institute of Certified Accountants (the "HKICPA"). As at December 31, 2015, the Company's net assets were HK\$693.2 million (equivalent to RMB580.7 million) after deducting the provisions for doubtful debts and other provisions. As at the date of this financial statement, the Company does not have any financial liabilities.

5.2 Dividends

The final dividend distribution for the year ended December 31, 2015 (the "2015 Financial Year") was approved at the 11th meeting of the Board of Directors of the Company (the "Board") on January 14, 2016. The 2015 Financial Year was held on January 14, 2016. The Board will be distributing the final dividend of the Company for the year ended December 31, 2015 (the "2015 Financial Year") on January 24, 2016 (the "2016 Financial Year").

The dividend of the Company will be paid on March 15, 2016 to January 14, 2016, both inclusive, to the shareholders of the Company who are registered in the Hong Kong Share Register. The dividend will be effected. The dividend of the Company will be paid on March 15, 2016 to January 14, 2016, both inclusive, to the shareholders of the Company who are registered in the Hong Kong Share Register.

Who are entitled to attend and vote at the AGM, all have a fee deposited
accounted by the relevant certificate holder to be lodged with the
Company's H Share Registrar, Computershare Hong Kong Investor Services
Ltd. (Company) at Sh 1712-1716, 17th Floor, H elliott Centre,
183 Queen's Road East, Wanchai, Hong Kong till late than 4:30 p.m.
May 13, 2016.

The amount of final dividend distribution shall be calculated based
on the total number of shares of the Company (the) in issue as of
December 31, 2015 and the final cash dividend distribution shall be based
on RMB0.25 per Share (including applicable tax). In addition, if
the Proposed Final Dividend, the holder of H Shares entitled to all have
certificate accounted by the relevant fee deposited with the Company
(address: Sh 1712-1716, 17/F, H elliott Centre, 183 Queen's Road East,
Wanchai, Hong Kong) before 4:30 p.m. on June 17, 2016. For the
purpose of a certain Shareholder who is entitled to the Proposed Final Dividend,
the registration fee for H Shares will be closed from June 19, 2016 to
June 24, 2016 (both dates inclusive).

The Proposed Final Dividend will be denominated and declared in RMB. The
holder of domestic Shares will be paid in RMB and the holder of H Shares
will be paid in Hong Kong dollars. The exchange rate of the Proposed Final
Dividend to be paid in Hong Kong dollars will be the rate of the exchange
rate of Hong Kong dollars to RMB as announced by the People's Bank of
China during the five business days prior to the date of declaration of the
Proposed Final Dividend.

In accordance with the Enterprise Income Tax Law of the People's
Republic of China (中華人民共和國企業所得稅法) and its implementing
regulations which came into effect on January 1, 2008, the Company is
entitled with the dividend income tax at the rate of 10%
on behalf of the - dividend Shareholder who are a shareholder
the registration fee for H Shares who are distributing the cash dividend.
As H Shares are registered under the name of a individual Shareholder,
including HKSCC Nominees Limited, the , agent ,
the organization , shall be deemed as Shares held by
- dividend Shareholder. Therefore, this basis, the
income tax shall be withheld from dividend payable to each Shareholder.
If holder of H Shares intend to change its Shareholder status, please
submit the relevant documents with the agent . The Company
will strictly comply with the law the relevant of the relevant
regulate that it is a dividend income tax on behalf
of the Shareholder based on the registration fee for H Shares as
of the Record Date.

If the i di id al h lde f H Sha e a e H g K g Maca e ide t e ide t f the c tie which had a ag eed ta ate f 10% f the ca h di ide d t the with the PRC de the ele a tta ag ee e t, the C a h ld with h ld a d a i di id al i c eta behalf f the ele a t Sha eh lde at a ate f 10%. Sh ld the i di id al h lde f H Sha e be e ide t f the c tie which had a ag eed ta ate f le tha 10% with the PRC de the ele a tta ag ee e t, the C a hall with h ld a d a i di id al i c eta behalf f the ele a t Sha eh lde at a ate f 10%. I that ca e, if the ele a t i di id al h lde f H Sha e i h t e clai the e t a a t with h ld d e t the a l i c a t i f 10% ta ate, the C a ca a l f the ele a t ag eed e f e t i a t a t e a t e t i d e d that the ele a t Sha eh lde b i t the e ide ce e i e d b the t i c e f the ta ag ee e t t C te ha e. The C a ill a i t with the ta e f d a f e the a al f the c e t e t ta a th i t . Sh ld the i di id al h lde f H Sha e be e ide t f the c tie which had a ag eed ta ate f e 10% b t le tha 20% with the PRC de the ta ag ee e t, the C a hall with h ld a d a the i di id al i c eta at the ag eed a t a l a t e i acc d a ce with the ele a tta ag ee e t. I the ca e that the i di id al h lde f H Sha e a e e ide t f the c tie which had a ag eed ta ate f 20% with PRC, which ha t e t e d i t a ta ag ee e t with PRC, the i e, the C a hall with h ld a d a the i di id al i c eta at a ate f 20%.

5.3 ,

During the period of the Litigation Date to December 31, 2015, either the Company or the subsidiary is charged, identified and affected by the Company's limited liability.

5.4 A

The C a ' a d i t c i t e e h a e i e d t h e G ' a a l e l f
t h e f i a c i a l e a e d e d D e c e b e 31, 2015 a d h a i e d t h a a l i c a b l e
a c c t i g t a d a d a d e i e e t h a e b e e c l i e d i t h a d t h a t
a d e a t e d i c l e h a e b e e a d e b t h e C a .

The Chartered Accountants in Hong Kong have appointed the Executive Director of the Chartered Accountants, M. HUANG Zhi (the chairman of the Chartered Accountants) and M. WONG Raymond Fok Lai, as the Executive Director of the Chartered Accountants, M. HE Xi. As the Chartered Accountants, M. HUANG Zhi has the appropriate professional qualifications (a Certified Public Accountant accredited by the Chinese Institute of Certified Public Accountants (中國註冊會計師協會)).

6 C A C E C A E A C E C D E

The C a c lied with all c de i i i the C ate G e a ce C de (the C C) et i i A e di 14 t the R le G e i g the Li ti g f Sec itie The St ck E cha ge f H g K g Li ited d i g the e i d f the Li ti g Date t Dece be 31, 2015, a e f the de iati f c de i i A.2.7 hich a i a il d et the h t e i d f ti e f the Li ti g Date t Dece be 31, 2015. C de i i A.2.7 e i e that the chai a h ld at lea t a l h ld eeti g with the -e ec ti e di ect (i cl di g i de e de t -e ec ti e di ect) with t the e ec ti e di ect e e t. The C a ha c ited t aki g ece a a a ge e t t c l with all the c de i i . The C a ill c ti e t e i e a de ha ce i t c ate g e a ce t e e that it ill c ti e t e e t the e i e e t f the C ate G e a ce C de.

7 F A C A E

7.1 C

The fig e i thi a ce e t f the G ' e l t f the ea e ded Dece be 31, 2015 ha e bee ag eed b the C a ' e te al a di t , P ice ate h e C e (C), t the a t et i i the G ' a d ited c l idated fi a cial tate e t f the ea e ded Dece be 31, 2015. The k e f ed b P C i thi e ec t di d t c ti t e a a a ce e gage e t i acc da ce with H g K g Sta da d A di ti g, H g K g Sta da d Re i e E gage e t H g K g Sta da d A a ce E gage e t i ed b the H g K g I ti t e f Ce ti fied P blic Acc ta t a d c e e t l , a a ce ha bee e e ed b P C thi a ce e t.

7.2 A

C a ed t the la t a d ited fi a cial tate e t f the G , the e a e ig i f i c a t cha ge t acc ti g l i c i e .

7.3 Financial Results

7.3.1 Consolidated Statement of Comprehensive Income

	December 31, 2015 RMB'000	December 31, 2014 RMB'000
Revenue	343,674	296,296
Cost of revenue	(213,289)	(181,313)
	<u>130,385</u>	<u>114,983</u>
Other income	3,074	689
Other loss	(144)	(151)
Selling expense	(1,970)	(2,092)
Administrative expense	(62,520)	(45,611)
	<u>68,825</u>	<u>67,818</u>
Financial income	11,625	749
Financial expense	(4,002)	
Finance income	<u>7,623</u>	<u>749</u>
Share of profits of equity accounted for in the consolidated	(6,278)	
Income tax expense	70,170	68,567
	<u>(18,548)</u>	<u>(17,369)</u>
	<u>51,622</u>	<u>51,198</u>
Other comprehensive income		
	<u>51,622</u>	<u>51,198</u>
Attributable to:		
Equity holders of the Company	55,709	51,198
Non-controlling interest	(4,087)	
	<u>51,622</u>	<u>51,198</u>
Earnings per share		
Basic and diluted (in RMB)	<u>1.03</u>	<u>1.02</u>

7.3.2 Consolidated Balance Sheets

	A D 2015 RMB'000	31, 2014 RMB'000
A E		
-		
P et , la ta de i et	233,200	160,799
La d e ight	20,738	21,210
I ta gible a et	90,581	1,229
I et et i a a ciate	8,422	
Defe ed i c et a a et	10,071	4,641
De it a d e a et	48,324	13,904
	<u>411,336</u>	<u>201,783</u>
C		
I e t ie	7,506	7,911
Ta de eei able	123,067	84,532
Othe eei able , de it a d e a et	42,690	27,340
A i t d e f elated a tie	20,044	13,502
Te de it	251,334	
Ca h a d ca h e i ale t	368,457	37,271
	<u>813,098</u>	<u>170,556</u>
	<u>1,224,434</u>	<u>372,339</u>
E		
E C		
C		
Sha e ca ital	73,040	50,000
Ca ital e e e	797,510	159,153
S l e e e	11,342	5,708
Retai ed ea i g	77,824	46,229
	<u>959,716</u>	<u>261,090</u>
N -c t lli g i te et	2,513	
	<u>962,229</u>	<u>261,090</u>

	A D 2015 RMB'000	31, 2014 RMB'000
LIABILITIES		
-		
Deferred government	14,284	14,156
Long-term payable	98,821	12,688
	<u>113,105</u>	<u>26,844</u>
C		
Trade payable	19,976	23,829
Accrual and other payable	63,209	47,340
Contractual liabilities	11,559	13,236
Bank borrowing	50,000	
Contractual long-term payable	4,356	
	<u>149,100</u>	<u>84,405</u>
	<u>262,205</u>	<u>111,249</u>
	<u>1,224,434</u>	<u>372,339</u>

7.4 Financial Information

7.4.1 General Information

The Company was established as a joint stock company in the People's Republic of China (Weizhou Kangning Mental Rehabilitation Hospital (温州市康宁精神康复医院)) in the PRC on February 7, 1996. The address of the Company's registered office is at Shengji Road, Hangzhou Residential District, Weizhou, Zhejiang, the PRC.

On October 15, 2014, the Company was converted into a joint stock limited company and named Weizhou Kangning Hospital Co., Ltd. (温州康宁医院股份有限公司).

The Group is engaged in the psychiatric hospital in the PRC.

The Company had its initial public offering on the Stock Exchange of Hong Kong on November 20, 2015.

The consolidated financial statements are presented in RMB and expressed in the PRC Renminbi Yuan, unless otherwise stated.

7.4.2 Basis of Preparation

The consolidated financial statements of the Group have been prepared in accordance with the IFRS. The consolidated financial statements have been prepared on the historical cost basis.

(a) New and amended standards adopted by the Group

The following standards and amendments have been adopted by the Group for the financial year beginning after January 1, 2015:

Amended IAS 19 'Contributions to employee benefit plans'.

Amended financial instruments IFRS 2010-2012 Cycle, IFRS 8, 'Operating segments', IAS 16, 'Property, plant and equipment', IAS 38, 'Intangible assets' and IAS 24, 'Related party disclosures'.

Amended financial instruments IFRS 2011-2013 Cycle, IFRS 3, 'Business combinations', IFRS 13, 'Fair value measurement'.

Amended IAS 27 'Earnings per share financial statement'.

The directors of the Company noted that the adoption of the amended IFRS had no material impact on the Group's earnings and financial position.

(b) New Hong Kong Companies Ordinance (Cap. 622)

In addition, the effect of Part 9 Accounting and Audit of the new Hong Kong Companies Ordinance (Cap. 622) came into effect during the financial year, as a result, the exchange of the related disclosures of certain financial information of the consolidated financial statements.

(c) *New standards and interpretations not yet adopted*

As at the end of the reporting period, the Group has not yet adopted the new standards and interpretations that are effective for annual periods beginning on or after January 1, 2015 and have not been applied in the consolidated financial statements. None of the new standards and interpretations is expected to have a significant effect on the consolidated financial statements of the Group, except the following:

IFRS 9, 'Financial Instruments'

IFRS 15, 'Revenue from Contracts with Customers'

IFRS 16, 'Leases'

The Group has assessed the IFRS and IFRIC interpretations that are expected to be effective that should be expected to have a material impact on the Group.

7.4.3 Trade Receivables

	At December 31, 2015 RMB'000	2014 RMB'000
Trade receivable	130,738	89,537
Less: provision for doubtful trade receivable	<u>(7,671)</u>	<u>(5,005)</u>
Trade receivable net	<u><u>123,067</u></u>	<u><u>84,532</u></u>

The carrying amount of the Group's trade receivable as determined in RMB, and a detailed breakdown of their fair value is as follows:

As of December 31, 2014 and 2015, the aging analysis of the trade receivable is as follows:

	As of 2015 RMB'000	31, 2014 RMB'000
Aging analysis based on the billing date:		
Bill to date	9,580	9,927
1-3 months	74,718	45,694
4-6 months	19,635	13,082
7-12 months	19,937	14,635
1-2 years	5,075	4,574
2-3 years	1,426	1,544
Over 3 years	367	81
	<u>130,738</u>	<u>89,537</u>

According to the Group's terms of business, all bills are due within 12 months.

As of December 31, 2014 and 2015, the Group's trade receivable is aged as follows: RMB73,442,000 and RMB113,297,000, respectively. The ageing is related to the amount to be claimed for local sales in accordance with the ageing of the trade receivable which are recoverable from the independent medical insurance companies. The ageing is based on the ageing of the medical insurance companies.

The ageing is based on the ageing of the trade receivable. The aging analysis of the trade receivable is as follows:

	As of 2015 RMB'000	31, 2014 RMB'000
Less than 1 year	110,355	71,136
1-2 years	2,800	2,269
2-3 years	142	3
Over 3 years	<u>113,297</u>	<u>73,442</u>

As of December 31, 2014 and 2015, trade receivable of RMB6,168,000 and RMB7,861,000 were included, respectively. The amount of the allowance for doubtful accounts was RMB5,005,000 and RMB7,671,000 as of December 31, 2014 and 2015, respectively. The aging of the trade receivable is as follows:

	As of December 31, 2015 RMB'000	2014 RMB'000
Less than 1 year	3,935	2,275
1-2 years	2,275	2,305
2-3 years	1,284	1,541
Over 3 years	367	47
	<u>7,861</u>	<u>6,168</u>

Management of the Group's trade receivable is as follows:

	As of December 31, 2015 RMB'000	2014 RMB'000
At January 1,	5,005	3,699
Provision of receivable	4,907	2,957
Receivable written off as collectible	(2,241)	(1,304)
Write-back received		(347)
	<u>7,671</u>	<u>5,005</u>

The provision of receivable is calculated based on the aging method. The management has reviewed the aging of receivable and the provision of receivable is considered adequate. The management has also reviewed the aging of receivable and the provision of receivable is considered adequate.

The management has reviewed the aging of receivable and the provision of receivable is considered adequate. The management has also reviewed the aging of receivable and the provision of receivable is considered adequate.

7.4.4 Other Receivables, Deposits and Prepayments

	A D 2015 RMB'000	31, 2014 RMB'000
Other receivable ^(a)	14,337	1,408
Deposit ^(b)	17,268	16,823
Amount due by third party ^(c)	12,304	
Prepayment	30,007	16,686
Prepayment for purchase of equipment ^(d)	13,000	
Prepayment for construction of engineering	2,594	1,216
Prepayment for goods and services	2,539	1,511
Prepayment for IPO fees		3,477
Other	43	123
Less: impairment of other receivable	(1,078)	
Total	<u>91,014</u>	<u>41,244</u>
Contract	42,690	27,340
Non-contract	48,324	13,904
Total	<u>91,014</u>	<u>41,244</u>

The carrying amount of the Group's other receivable, deposit and prepayment as at the end of the reporting period is RMB 91,014,000, which is classified as follows:

(a) Included in other receivable as at December 31, 2015 is a receivable of RMB9,210,000 from Ya Jia Fei Hospital. Such receivable will be repaid to the Group by Ya Jia Fei Hospital when the hospital is fully paid for the receivable.

(b) Included in deposit as at December 31, 2014 and 2015 is a deposit of RMB12,688,000 from the construction of the hospital. The deposit is for the guarantee of the construction of the hospital. The deposit will be repaid to the Group after the construction is completed and all Group's obligations have been discharged.

(c) The Company entered into an agreement with Sichuan Hengji Pharmaceutical Co., Ltd. (the "Company"), a subsidiary of the Group, in March 2015 and entered into a certain business with Sichuan Hengji. The Company placed a deposit of RMB12,000,000 to Sichuan Hengji as a capital contribution. Subsequently, the agreement was cancelled and the Company entered into an agreement with Sichuan Hengji, Chengdu Jihong Hospital Co., Ltd. (the "Company"), a subsidiary of the Group, and the Company

f Sich a H gji) a d the C a J e 29, 2015. P a t t the
le e tal age e e t, the the a tie age e d t aba d the b i e la
a d the de it h ld be e aid b Che gd Jih gt the G . Withi 12
th c e ci g f J e 29, 2015, bea i g a i te e t ate f 5% e
a . The a i g a a teed b the ha eh lde f Sich a H gji.

O J.1 28, 2015, Che d Jih g cha ged it a e t Che gd Re i H ital
C a Li ited.

(d) The C a e te e d i t a age e e t With Pi g a g Mi tia S ecialized
F d C e a t i e (, a i de e de t t h i d a t) i
Oct be 2015 t cha e a e t f Pi g a g Mi tia . The t tal
c ide a t i f the e t i RMB18,000,000. A f Dece be 31, 2015,
RMB13,000,000 a aid t Pi g a g Mi tia .

7.4.5 Accruals and Other Payables

	A 2015 RMB'000	D 31, 2014 RMB'000
Acc ed e l ee be efit	18,637	17,939
Recei t i ad a ce	3,194	3,416
Re tal a able	3,004	3,362
G a a tee de it ecei ed f c t i c t i c t a c t (a)	12,688	12,688
Othe a able f e t , la t a d e i e t	20,831	19,916
Othe ta e a able	412	641
Ad a ce ecei ed f a -c t lli g ha eh lde (b)	3,110	1,500
L g-te a able f c t a c t al ight t ide a age e t e ice	90,489	
Acc ed li ti ge e e	11,606	
Othe	2,415	566
	166,386	60,028
C e t	63,209	47,340
C e t ti fl g-te a able f c t a c t al ight t ide a age e t e ice	4,356	
N -c e t	98,821	12,688
	166,386	60,028

The carrying amount of accumulated depreciation is RMB. The carrying amount is at their fair value at their respective dates.

- (a) The amount paid by the contract of the health insurance contract is the amount of the contract. The amount will be paid to the contract after it discharges all its obligations under the contract, including but not limited to full settlement of the contract. The amount is the amount of the contract.
- (b) It is the amount received from the contract of the health insurance contract. The amount is the amount of the contract.

7.4.6 Revenue

	2015	2014
	RMB'000	RMB'000
Treatment and general healthcare service	240,103	206,790
Pharmaceutical sales	87,740	77,384
Accommodation service	2,270	1,828
Management service fee	13,561	10,294
	343,674	296,296

7.4.7 Expenses by Nature

	D 2015 RMB'000	31, 2014 RMB'000
Employee benefit expense	99,988	82,750
Pharmaceutical and consumable	86,483	75,419
Depreciation and amortization	21,706	15,067
Operating lease expense	8,563	10,055
Operating lease expense related to health care facilities	7,388	6,612
Catering expense	11,280	8,404
Utilities expense	5,820	5,381
Advertising fee	3,388	3,900
Profit sharing benefit expense	4,907	2,610
Profit sharing benefit expense	1,078	
Travel expense	2,481	3,086
Promotional advertising	1,970	2,092
Donation	1,814	1,834
Charitable contribution	345	1,147
Litigation expense	5,177	
Administrative expense	1,532	315
Non-administrative expense		
Other	13,859	10,344
	277,779	229,016

7.4.8 Income Tax Expense

The income tax expense of the Group for the year ended December 31, 2014 and 2015 is analyzed as follows:

	2015 RMB'000	31, 2014 RMB'000
Current income tax:		
PRC current income tax	23,978	19,054
Deferred income tax	(5,430)	(1,685)
	<u>18,548</u>	<u>17,369</u>

The tax on the Group's profit before income tax differs from the theoretical amount that would arise if the tax rate of the PRC, the principal place of the Group's operations, applied as follows:

	2015 RMB'000	31, 2014 RMB'000
Profit before income tax	70,170	68,567
Calculated at the tax rate of 25%	17,543	17,142
Excess tax deductible	2,507	227
Income tax subject to	(167)	
One-off income tax	(1,335)	
	<u>18,548</u>	<u>17,369</u>

PRC corporate income tax

The income tax liability of the Group is effected from operations in the PRC has been calculated at the tax rate of 25% that is stipulated as a taxable profit of the year, based on the existing legislation, interpretation and practice in effect the effective fiscal tax rate is applicable.

7.4.9 Earnings per Share

Basic earnings per share

The calculation of basic earnings per share is based on the attributable profit held by the Company of RMB51,198,000 and RMB55,709,000 for the ended December 31, 2014 and 2015, respectively, and the weighted average number of shares in issue at the end of each reporting period, calculated as follows:

Weighted average number of ordinary shares

	December 31, 2015	December 31, 2014
	No. of shares	No. of shares
Ordinary shares issued at beginning of the period	50,000,000	50,000,000
Effect of increase of share	<u>4,253,370</u>	<u> </u>
Weighted average number of shares held at the end of the period	<u><u>54,253,370</u></u>	<u><u>50,000,000</u></u>

The Company executed its authorized capital on October 15, 2014. The calculation of earnings per share for the ended December 31, 2014 is based on 50,000,000 ordinary shares in issue at the end of the period. The Company executed its authorized capital on October 15, 2014. The calculation of earnings per share for the ended December 31, 2015 is based on 54,253,370 ordinary shares in issue at the end of the period.

Diluted earnings per Share

The Company did not have any potential dilutive shares at the end of the period. Accordingly, diluted earnings per share are the same as the basic earnings per share.

7.4.10 Final Dividends

On March 11, 2015, the Board declared a final dividend of RMB18,480,000 for the year ended December 31, 2014. The dividend was paid to the Shareholders by the Company on July 1, 2015 and the Company paid out the dividend on July 23, 2015.

On March 24, 2016, the Board declared a final dividend of RMB18,260,000 for the year ended December 31, 2015 which is calculated based on 73,040,000 issued Shares as of December 31, 2015. The dividend is expected to be reflected in the consolidated financial statements as of December 31, 2015, and will be reflected in the consolidated financial statements as of December 31, 2016.

	December 31, 2015 RMB'000	December 31, 2014 RMB'000
Paid final dividend of RMB0.25 (2014: RMB0.35) to the Shareholders	<u>18,260</u>	<u>18,480</u>

7.4.11 Commitments

Capital commitments

	December 31, 2015 RMB'000	December 31, 2014 RMB'000
Contracted but not provided for		
construction buildings	36,635	86,130
leasehold improvements	60,529	1,784
equipment, land and other	<u>10,935</u>	<u>794</u>
	<u>108,099</u>	<u>88,708</u>

Operating lease commitments

The Group has lease commitments for office buildings and other immovable property under non-cancellable operating lease agreements.

The Group's future aggregate minimum lease payments under non-cancellable operating leases are as follows:

	A D 2015 <i>RMB'000</i>	31, 2014 <i>RMB'000</i>
Not later than 1 year	28,593	26,654
Later than 1 year and not later than 5 years	74,546	80,867
Later than 5 years	105,831	129,116
	208,970	236,637

Investment in subsidiaries

	A D 2015 <i>RMB'000</i>	31, 2014 <i>RMB'000</i>
Not later than 1 year	43,000	8,600
Later than 1 year and not later than 5 years	15,600	2,400
	58,600	11,000

7.4.12 Principal Subsidiaries

The following is a list of the official websites of the C... as of December 31, 2015:

					(%)	(%)
Cangnan Kangning Hospital Co., Ltd. (蒼南康寧醫院有限公司)	The PRC, Limited liability company	Private company in PRC	Paid-in capital of RMB1,000,000		100%	100%
Qingtian Kangning Hospital Co., Ltd. (青田康寧醫院有限公司)	The PRC, Limited liability company	Private company in PRC	Paid-in capital of RMB1,000,000		100%	100%
Yongjia Kangning Hospital Co., Ltd. (永嘉康寧醫院有限公司)	The PRC, Limited liability company	Private company in PRC	Paid-in capital of RMB1,000,000		100%	100%
Yueqing Kangning Hospital Co., Ltd. (樂清康寧醫院有限公司)	The PRC, Limited liability company	Private company in PRC	Paid-in capital of RMB1,000,000		100%	100%
Shenzhen Yining Hospital Co., Ltd. (深圳市怡寧醫院有限公司)	The PRC, Limited liability company	Private company in PRC	Paid-in capital of RMB16,600,000		52%	48%
Wenzhou Kangning Judicial Forensic Center (溫州康寧司法鑒定所)	The PRC, Sole proprietorship enterprise	For-profit company in PRC	Paid-in capital of RMB500,000		100%	100%
Linhai Kangning Hospital Co., Ltd. (臨海康寧醫院有限公司)	The PRC, Limited liability company	Private company in PRC	Paid-in capital of RMB2,000,000		80%	80%
Wenzhou Yining Geriatric Hospital Co., Ltd. (溫州怡寧老年醫院有限公司) ^(a)	The PRC, Limited liability company	Private company in PRC	Paid-in capital of RMB10,000,000		100%	100%
Pingyang Kangning Hospital Co., Ltd. (平陽康寧醫院有限公司) ^(b)	The PRC, Limited liability company	Private company in PRC	Paid-in capital of RMB6,000,000		100%	100%
Shenzhen Yining Medical Investment Co., Ltd. (深圳怡寧醫療投資有限公司) ^(c)	The PRC, Limited liability company	Investment holding company in PRC	Nil		100%	100%
Qingzhou Yining Hospital Co., Ltd. (衢州怡寧醫院有限公司) ^(d)	The PRC, Limited liability company	Private company in PRC	Nil		60%	40%
Hangzhou Honglan Information Technology Co., Ltd. (杭州宏瀾信息科技有限公司) ^(e)	The PRC, Limited liability company	Online company in PRC	Nil		100%	100%
Lanfang Yining Hospital Management Co., Ltd. (廊坊市怡寧醫院管理有限公司) ^(f)	The PRC, Limited liability company	Holding company in PRC	Nil		100%	100%

All the subsidiaries are established in the PRC as limited liability companies in the People's Republic of China, which are listed hereinafter.

- (a) Weizhuo Yiyi Genetic Hospital Co., Ltd. was established on November 2, 2015 with a registered capital of RMB10,000,000. Its paid-up capital was RMB10,000,000 as of December 31, 2015.
- (b) Pingang Kangyi Hospital Co., Ltd. was established on November 2, 2015 with a registered capital of RMB6,000,000. Its paid-up capital was RMB6,000,000 as of December 31, 2015.
- (c) Shezhen Yiyi Medical Internet Co., Ltd. was established on September 23, 2015 with a registered capital of RMB10,000,000. Its paid-up capital was RMB10,000,000 as of December 31, 2015.
- (d) Qizhuo Yiyi Hospital Co., Ltd. was established on November 20, 2015 with a registered capital of RMB30,000,000. Its paid-up capital was RMB30,000,000 as of December 31, 2015.
- (e) Hangzhou Hengli Intelligent Technology Co., Ltd. was established on November 20, 2015 with a registered capital of RMB5,000,000. Its paid-up capital was RMB5,000,000 as of December 31, 2015.
- (f) Laogang Yiyi Hospital Management Co., Ltd. was established on December 2, 2015 with a registered capital of RMB10,000,000. Its paid-up capital was RMB10,000,000 as of December 31, 2015.

Bodong Baodong
  C., Ltd.
 Chairman

Zhejiang, the PRC
 March 29, 2016

As of the date of this announcement, the Company's executive directors are Mr. GUAN Weili, Ms. WANG Lianyue and Ms. WANG Hongyue; the non-executive directors are Mr. YANG Yang and Ms. HE Xin; and the independent non-executive directors are Mr. CHONG Yat Keung, Mr. HUANG Zhi and Mr. WONG Raymond Fook Lam.